Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 173


Is performing lobectomy after the use of bevacizumab for a lung tumor dangerous?

Uramoto H, Nakajima Y, Kinoshita H.

Ann Med Surg (Lond). 2016 Jan 27;6:46-9. doi: 10.1016/j.amsu.2016.01.081. eCollection 2016 Mar.


TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM.

Lancet Oncol. 2016 Feb;17(2):212-23. doi: 10.1016/S1470-2045(15)00483-0. Epub 2015 Dec 23.


Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer.

Kubota T, Okano Y, Sakai M, Takaoka M, Tsukuda T, Anabuki K, Kawase S, Miyamoto S, Ohnishi H, Hatakeyama N, Machida H, Urata T, Yamamoto A, Ogushi F, Yokoyama A.

Anticancer Res. 2016 Jan;36(1):307-12.


Cost Analyses in the US and Japan: A Cross-Country Comparative Analysis Applied to the PRONOUNCE Trial in Non-Squamous Non-Small Cell Lung Cancer.

Hess LM, Rajan N, Winfree K, Davey P, Ball M, Knox H, Graham C.

Adv Ther. 2015 Dec;32(12):1248-62. doi: 10.1007/s12325-015-0270-9. Epub 2015 Dec 9.


Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.

Brady AK, McNeill JD, Judy B, Bauml J, Evans TL, Cohen RB, Langer C, Vachani A, Aggarwal C.

Oncotarget. 2015 Oct 6;6(30):30287-94. doi: 10.18632/oncotarget.4711.


A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.

Dingemans AM, Groen HJ, Herder GJ, Stigt JA, Smit EF, Bahce I, Burgers JA, van den Borne BE, Biesma B, Vincent A, van der Noort V, Aerts JG; NVALT study group.

Ann Oncol. 2015 Nov;26(11):2286-93. doi: 10.1093/annonc/mdv370. Epub 2015 Sep 7.


Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller JH, Smith TJ, Strawn JR, Trent D, Johnson DH; American Society of Clinical Oncology Clinical Practice.

J Clin Oncol. 2015 Oct 20;33(30):3488-515. doi: 10.1200/JCO.2015.62.1342. Epub 2015 Aug 31. Erratum in: J Clin Oncol. 2016 Apr 10;34(11):1287.


Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.

Behera M, Pillai RN, Owonikoko TK, Kim S, Steuer C, Chen Z, Saba NF, Belani CP, Khuri FR, Ramalingam SS.

J Thorac Oncol. 2015 Aug;10(8):1142-7. doi: 10.1097/JTO.0000000000000572. Review.


Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.

Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS, Villalona-Calero MA, Otterson GA.

Clin Lung Cancer. 2015 Nov;16(6):466-74. doi: 10.1016/j.cllc.2015.05.004. Epub 2015 May 13.


Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.

Kumar G, Woods B, Hess LM, Treat J, Boye ME, Bryden P, Winfree KB.

Lung Cancer. 2015 Sep;89(3):294-300. doi: 10.1016/j.lungcan.2015.05.020. Epub 2015 Jun 3.


Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer.

Carroll NM, Delate T, Menter A, Hornbrook MC, Kushi L, Aiello Bowles EJ, Loggers ET, Ritzwoller DP.

J Oncol Pract. 2015 Sep;11(5):356-62. doi: 10.1200/JOP.2014.002980. Epub 2015 Jun 9.


BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.

Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY.

J Clin Oncol. 2015 Jul 1;33(19):2197-204. doi: 10.1200/JCO.2014.59.4424. Epub 2015 May 26.


Lung cancer drug therapy in Hungary - 3-year experience.

Moldvay J, Rokszin G, Abonyi-Tóth Z, Katona L, Fábián K, Kovács G.

Onco Targets Ther. 2015 May 13;8:1031-8. doi: 10.2147/OTT.S65794. eCollection 2015.


Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.

Masuda T, Imai H, Kuwako T, Miura Y, Yoshino R, Kaira K, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M.

Clin Transl Oncol. 2015 Sep;17(9):702-9. doi: 10.1007/s12094-015-1297-8. Epub 2015 May 20.


The role of anti-angiogenesis in non-small-cell lung cancer: an update.

Villaruz LC, Socinski MA.

Curr Oncol Rep. 2015 Jun;17(6):26. doi: 10.1007/s11912-015-0448-y. Review.


Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Balducci L, Ciardiello F, Di Maio M, Felip E, Langer C, Lilenbaum RC, Perrone F, Senan S, de Marinis F.

Clin Lung Cancer. 2015 Sep;16(5):325-33. doi: 10.1016/j.cllc.2015.02.006. Epub 2015 Mar 7. Review.


MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer.

Hiura K, Shiraishi A, Suzuki C, Takamura K, Yamamoto M, Komori H, Watanabe Y, Iwaki-Egawa S.

Cancer Biomark. 2015;15(4):433-40. doi: 10.3233/CBM-150483.


Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.

Besse B, Le Moulec S, Mazières J, Senellart H, Barlesi F, Chouaid C, Dansin E, Bérard H, Falchero L, Gervais R, Robinet G, Ruppert AM, Schott R, Léna H, Clément-Duchêne C, Quantin X, Souquet PJ, Trédaniel J, Moro-Sibilot D, Pérol M, Madroszyk AC, Soria JC.

Clin Cancer Res. 2015 Apr 15;21(8):1896-903. doi: 10.1158/1078-0432.CCR-14-2082. Epub 2015 Jan 22.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk